SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Concordium is the Layer-1 blockchain built for a new era of digital trust. With mandatory, privacy-preserving identity verification built into its consensus layer, utilizing zero-knowledge proof technology. Concordium also enables Protocol-level tokens that eliminate smart contract risks by being issued directly at the consensus layer, with built-in features that provide the infrastructure for compliance-ready use cases. At its core is Smart Money - programmable, identity-embedded, and compliance-ready value that powers trusted interactions across Web3. Smart Money enables frictionless exchange, automation, and verifiable trust by design. Unlike conventional blockchains, Concordium integrates trust, accountability, and privacy into its architecture from the ground up  bridging traditional systems and Web3 to build a transparent, sustainable digital future. The name Concordium comes from the Latin concordia—meaning harmony and agreement—a reflection of its mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.

Concordium

Concordium ($CCD) is trending as community members highlight its focus on compliance, privacy, and real-world utility, particularly its advancements in stablecoins and PayFi. Recent partnerships, including integration with bitcoin.com wallets for age-verified stablecoin payments, are generating excitement. Many believe $CCD is positioned to be a key infrastructure player in the evolving regulatory landscape of blockchain and digital finance.

DigitalOcean Holdings, Inc. engages in the provision of providing cloud infrastructure. It operates through the following geographical segments: United States, Netherlands, Germany, Canada, Singapore, and Other. The company was founded in 2012 and is headquartered in Broomfield, CO.

DigitalOcean Holdings Inc

DigitalOcean ($DOCN) is trending as investors discuss recent analyst upgrades and positive earnings reports, with some highlighting its potential as an AI cloud play. Community members are debating whether it's undervalued, with some pointing to its AMD partnership and recurring revenue, while others are eyeing it as a potential acquisition target. The stock's price action and potential breakout are also key talking points.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos ($XTZ) is trending amid discussions of potential pump and dumps, with community members debating whether recent price movements are sustainable or a trap for "suckers." The conversation revolves around identifying entry and exit points, as well as the coin's long-term potential in the broader crypto market, with some users pointing to its growing supply.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is gaining traction as community members highlight its growing user base, surpassing Solana and Ethereum in active users, which may be driving the current rally. Bullish sentiment is also fueled by discussions around AI integration and staking opportunities within the NEAR ecosystem. Traders are actively monitoring potential breakout setups and key price levels.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

$SWEAT is gaining attention as users discuss its potential and unique concept of earning crypto through physical activity. Community members are highlighting its long-term potential and staking opportunities. Some are calling for more immediate gains, while others remain patient, awaiting wider recognition and adoption.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community speculates on potential catalysts and price movements, drawing comparisons to Zcash's recent surge. Discussions revolve around Litecoin's historical position in crypto, its adoption for payments, and whether it's primed for a significant breakout, with some anticipating a rally towards higher price targets. However, skepticism remains, with some traders pointing to Litecoin's past underperformance and concerns about it being a 'scam pump'.

SSgA Active Trust - Health Care Select Sector SPDR

Health Care Select Sector SPDR Fund

The Health Care Select Sector SPDR Fund ($XLV) is trending as traders discuss potential breakout patterns and whether it's poised to challenge all-time highs. Bullish sentiment is fueled by rising A/D Line and MFI indicators, suggesting accumulation by institutional investors. Some are also pointing to the healthcare sector as undervalued compared to the broader market, anticipating a rotation into defensive stocks.

Giggle Fund

Giggle Fund is seeing active discussion around potential shorting opportunities and trading plans, with community members pointing to technical analysis and price targets. Some traders are expressing concerns about the fund's stability and potential connections to other cryptocurrencies, while others highlight its recent price movements and possible bullish scenarios. Speculation around market manipulation and external factors like potential tariffs are also circulating.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.

NeOnc Technologies Holdings Inc.

NeOnc Technologies is trending following news of a strategic partnership with Quazar Investment, including a significant equity investment at a premium. The community is discussing the potential for clinical trial advancements and infrastructure development in the UAE and MENA region as a result of this deal, with some highlighting the low float and potential for rapid price movement. Recent executive appointments and positive clinical trial updates have also contributed to increased interest in NTHI.

Sei is a high-performance Layer 1 blockchain that scales the EVM with parallelized execution, enabling faster transactions, low fees, and seamless smart contract deployment. Sei removes traditional blockchain bottlenecks while maintaining full Ethereum compatibility. The upcoming Giga upgrade will deliver 50x improvements in EVM throughput, optimizing execution, consensus, and storage to push blockchain performance to web2 levels.

SEI is trending as community members discuss its potential compared to other Layer-1 blockchains like SUI, with some anticipating a significant price increase. The addition of SEI to Robinhood is also being noted as a potential catalyst. Some users are discussing cup and handle formations and possible breakouts above $2.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aquestive Therapeutics (NASDAQ:AQST) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) released its earnings results on Wednesday. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus...

Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings

Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -7.69% and -4.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?

Here is how DBV Technologies S.A. (DBVT) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.

Are Medical Stocks Lagging  Aquestive Therapeutics (AQST) This Year?

Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.

Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?

Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Shares of Aquestive Therapeutics jumped more than 11% in after-hours trading Thursday after CEO Dan Barber said the company’s oral epinephrine film, Anaphylm, could become a “blockbuster” drug with as much as $1 billion in peak global sales.Barber&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/09/25/aquestive-ceo-on-its-potential-1-billion-blockbuster-product.html">said in an interview</a> on CNBC’s "Mad Money" with Jim Cramer, noting that despite winning six FDA approvals and distributing 2.5 billion doses worldwide over the past two decades, Aquestive has historically remained small, with annual revenue of $50 million to $70 million.&nbsp;He said Anaphylm, designed to treat severe allergic reactions with a dissolvable sublingual film instead of an auto-injector, represents the company’s first chance at a broad-market product.Cramer, who first highlighted the stock earlier this month as a speculative pick, pointed to Anaphylm’s potential as an alternative to epinephrine auto-injectors like the EpiPen.Earlier this month, Aquestive said that the FDA has determined an advisory committee meeting is not required for Anaphylm, maintaining the Prescription Drug User Fee Act target action date of January 31, 2026.&nbsp;Oppenheimer raised its price target on Aquestive to $8 from $7 following the announcement, reiterating its ‘Outperform’ rating and noting that investors interpret the FDA decision as increasing the chances of approval.The company has also outlined its regulatory strategy outside the U.S., saying in July that Health Canada granted a meeting to discuss its planned New Drug Submission for Anaphylm and that an initial briefing package has been submitted to the European Medicines Agency.&nbsp;Aquestive said Canada and Europe represent “ideal initial international markets” for the drug, given regulatory alignment and patient need.To prepare for a potential launch, Aquestive has raised about $160 million in financing, which Barber said positions the company to ensure broad outreach to providers, caregivers, and patients once the FDA decision is made.On Stocktwits, retail sentiment for Aquestive was ‘bullish’ amid ‘high’ message volume.One user said that Barber’s appearance on&nbsp;CNBC’s “Mad Money” show&nbsp;was a turning point for Aquestive Therapeutics, saying the CEO “really painted the company in a great light” by backing up Anaphylm’s projected value with current epinephrine market data.&nbsp;<stembedurl>https://stocktwits.com/YaBoyJ313/message/630079945</stembedurl>Another user suggested that Aquestive could become a buyout target within two years of Anaphylm sales, predicting the stock could climb from about $10 to $25 if that scenario&nbsp;were to play out.<stembedurl>https://stocktwits.com/ImPoorAndHungry/message/630067707</stembedurl><a href="https://stocktwits.com/symbol/AQST">Aquestive’s stock</a> has risen 47.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aquestive’s stock (AQST) has risen 47.8% so far in 2025. (Photo credit: Getty Images)

Aquestive Stock Jumps After-Hours As CEO Sees $1B ‘Blockbuster’ Potential For Oral Allergy Film — Retail Sees Stock As Buyout Candidate

Aquestive’s Anaphylm has drawn heightened investor attention after the CEO spotlighted it as the company’s first broad-market product.

Why Aquestive Therapeutics Stock Jumped After-Hours Today

Equity

Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?

Aquestive Therapeutics (AQST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.14	--	--	N/A
Q3 '25	-$0.13	-$0.14	-9.37%	MISSED
Q2 '25	-$0.17	-$0.14	16.00%	BEAT
Q1 '25	-$0.17	-$0.24	-45.45%	MISSED
Q4 '24	-$0.13	-$0.19	-42.92%	MISSED

AQST
Aquestive Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest AQST News

AQSTAquestive Therapeutics Inc